oxybutynin has been researched along with Obesity in 11 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment-emergent adverse events of 2% or greater in the LNG/EE contraceptive patch were nasopharyngitis (5." | 2.80 | Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women. ( Archer, DF; Foegh, M; Kaunitz, AM; Mishell, DR, 2015) |
| " However, the conventional approaches to apply browning agents systematically suffer from off-target effects, multiple dosage requirements, and poor patient compliance." | 2.72 | Strategies for Browning Agent Delivery. ( Gu, Z; Sheng, T; Zhang, W; Zhang, Y, 2021) |
| "Current treatments toward obesity including diet, physical exercise, pharmacological therapy, as well as surgeries are always associated with low effectiveness or undesired systematical side effects." | 1.46 | Locally Induced Adipose Tissue Browning by Microneedle Patch for Obesity Treatment. ( Gu, Z; Liu, Q; Qiang, L; Wang, J; Yu, J; Yu, S; Zhang, Y, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Lua, LL | 1 |
| Pathak, P | 1 |
| Dandolu, V | 1 |
| Zhang, W | 1 |
| Sheng, T | 1 |
| Gu, Z | 2 |
| Zhang, Y | 2 |
| Dangol, M | 1 |
| Kim, S | 1 |
| Li, CG | 1 |
| Fakhraei Lahiji, S | 1 |
| Jang, M | 1 |
| Ma, Y | 1 |
| Huh, I | 1 |
| Jung, H | 1 |
| Liu, Q | 1 |
| Yu, J | 1 |
| Yu, S | 1 |
| Wang, J | 1 |
| Qiang, L | 1 |
| Ariamoghaddam, AR | 1 |
| Ebrahimi-Hosseinzadeh, B | 1 |
| Hatamian-Zarmi, A | 1 |
| Sahraeian, R | 1 |
| Kaunitz, AM | 2 |
| Portman, D | 1 |
| Westhoff, CL | 2 |
| Archer, DF | 2 |
| Mishell, DR | 2 |
| Rubin, A | 1 |
| Foegh, M | 2 |
| Reinecke, I | 1 |
| Bangerter, K | 1 |
| Merz, M | 1 |
| Hurley, C | 1 |
| Semancik, L | 1 |
| Simmons, KB | 1 |
| Edelman, AB | 1 |
| Lycett, D | 1 |
| Munafò, M | 1 |
| Johnstone, E | 1 |
| Murphy, M | 1 |
| Aveyard, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-label, Randomized, Parallel Group, Study of Efficacy and Safety of a Transdermal Contraceptive Delivery System (TCDS) in Comparison to a Low-dose Oral Contraceptive Containing 0.02 mg EE and 0.1 mg LNG in a 21-day Regimen.[NCT01181479] | Phase 3 | 1,504 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measuring the breakthrough bleeding (BTB) and/or breakthrough spotting (BTS). Measured as a percent of total number of cycles in each Arm/Group with BTB and/or BTS. (NCT01181479)
Timeframe: 6 months
| Intervention | percentage of cycles with BTB/BTS (Number) |
|---|---|
| AG200-15 for Cycle 1-6 | 23.9 |
| Lessina | 21.2 |
"Evaluation of patch adhesion was determined using the following scores:~0: >= 90% adhered (no lift)~>= 75% adhered but < 90% (some edges showing lift)~>= 50% adhered but < 75% (half of system lifts off)~< 50% (> half of system lifts off, but undetached)~patch completely detached" (NCT01181479)
Timeframe: 1 year
| Intervention | Score on a scale (Mean) |
|---|---|
| All Subjects Who Applied AG200-15 | 0.29 |
Pregnancy outcomes was determine by measuring Pearl index. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use. (NCT01181479)
Timeframe: AG200-15: 6 months; Lessina: 6 months; AG200-15: 1 year
| Intervention | Pearl Index (Number) |
|---|---|
| AG200-15 for Cycle 7-13 | 5.41 |
| Lessina | 6.67 |
| AG200-15 for Cycle 1-13 | 6.43 |
"Evaluation of irritation at application site was determined using the following scores:~0: None~Mild~Moderate~Severe" (NCT01181479)
Timeframe: 1 year
| Intervention | Score on scale (Mean) |
|---|---|
| All Subjects Who Applied AG200-15 | 1.35 |
"Evaluation of itching at patch application site was determined using the following scores:~0: None~Mild~Moderate~Severe" (NCT01181479)
Timeframe: 1 year
| Intervention | Score on a scale (Mean) |
|---|---|
| All Subjects Who Applied AG200-15 | 1.48 |
Measurement of plasma concentrations of LNG and EE for cycles 2, 6 and 13. (NCT01181479)
Timeframe: Lessina: 6 months; AG200-15: 1 year; AG200-15: 6 months
| Intervention | pg/ml (Mean) | |||||
|---|---|---|---|---|---|---|
| EE for cycle 2 | EE cycle 6 | EE cycle 13 | LNG cycle 2 | LNG cycle 6 | LNG cycle 13 | |
| AG200-15 for Cycle 1-13 | 30.5 | 36.7 | 31 | 1201 | 1753 | 1590 |
| AG200-15 for Cycles 7-13 | NA | NA | 33.4 | NA | NA | 1750 |
| Lessina Cycles 1-6 | 35.4 | 40.1 | NA | 2386 | 2611 | NA |
2 reviews available for oxybutynin and Obesity
| Article | Year |
|---|---|
Strategies for Browning Agent Delivery.
Topics: Adipocytes, Brown; Adipocytes, White; Animals; Anti-Obesity Agents; Drug Delivery Systems; Humans; M | 2021 |
Hormonal contraception and obesity.
Topics: Administration, Cutaneous; Administration, Oral; Body Mass Index; Contraception; Contraception, Post | 2016 |
3 trials available for oxybutynin and Obesity
| Article | Year |
|---|---|
Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial.
Topics: Adolescent; Adult; Body Mass Index; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Dr | 2014 |
Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol/2.1-mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles.
Topics: Adolescent; Adult; Body Mass Index; Contraceptive Agents, Female; Drug Combinations; Estradiol; Ethi | 2014 |
Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
Topics: Adolescent; Adult; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Drug Combinations | 2015 |
6 other studies available for oxybutynin and Obesity
| Article | Year |
|---|---|
Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.
Topics: Adolescent; Adult; Cholinergic Antagonists; Female; Humans; Male; Mandelic Acids; Medication Adheren | 2017 |
Anti-obesity effect of a novel caffeine-loaded dissolving microneedle patch in high-fat diet-induced obese C57BL/6J mice.
Topics: Administration, Cutaneous; Animals; Anti-Obesity Agents; Caffeine; Cell Survival; Cholesterol; Diet, | 2017 |
Locally Induced Adipose Tissue Browning by Microneedle Patch for Obesity Treatment.
Topics: Adipocytes, White; Adipose Tissue, White; Animals; Anti-Obesity Agents; Drug Delivery Systems; Hypog | 2017 |
In vivo anti-obesity efficacy of curcumin loaded nanofibers transdermal patches in high-fat diet induced obese rats.
Topics: Adipose Tissue; Administration, Cutaneous; Animals; Cholesterol; Curcumin; Diet, High-Fat; Drug Libe | 2018 |
Transdermal Patches: Considerations in Special Populations.
Topics: Administration, Cutaneous; Age Factors; Cachexia; Humans; Obesity; Pharmaceutical Preparations; Tran | 2016 |
Associations between weight change over 8 years and baseline body mass index in a cohort of continuing and quitting smokers.
Topics: Adult; Aged; Body Mass Index; England; Family Practice; Female; Humans; Male; Middle Aged; Nicotine; | 2011 |